Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Chinese Patent Office
Merck
Federal Trade Commission
Moodys
Johnson and Johnson
US Department of Justice
Citi

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,436,989

« Back to Dashboard

Which drugs does patent 6,436,989 protect, and when does it expire?

Patent 6,436,989 protects LEXIVA and is included in two NDAs.

Protection for LEXIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-one patent family members in forty-three countries.
Summary for Patent: 6,436,989
Title: Prodrugs of aspartyl protease inhibitors
Abstract:The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.
Inventor(s): Hale; Michael R. (Bedford, MA), Tung; Roger D. (Arlington, MA), Baker; Christopher T. (Waltham, MA), Spaltenstein; Andrew (Raleigh, NC)
Assignee: Vertex Pharmaceuticals, Incorporated (Cambridge, MA)
Application Number:08/998,050
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,436,989
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 6,436,989

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,436,989

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,592,368 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
6,559,137 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
6,838,474 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,436,989

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Georgia, Republic of P20032923 ➤ Try a Free Trial
European Patent Office 0933372 ➤ Try a Free Trial PA2008006 Lithuania ➤ Try a Free Trial
European Patent Office 0933372 ➤ Try a Free Trial 91426 Luxembourg ➤ Try a Free Trial
European Patent Office 0933372 ➤ Try a Free Trial CA 2008 00027 Denmark ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chinese Patent Office
Julphar
Federal Trade Commission
Healthtrust
Fish and Richardson
QuintilesIMS
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.